Avaya Transforms Portugal’s Emergency Services Communications Systems to Prepare for eCall
Avaya Holdings Corp. (NYSE: AVYA) today announced that Portugal’s emergency services have adopted its suite of communication solutions to transform their existing systems in preparation for eCall, the next-generation automated vehicle aid system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606005478/en/
(Photo: Business Wire)
A life-saving innovation that is mandatory in all new passenger-vehicle types approved for sale in the European Union from April 2018, eCall allows telemetry data to be sent from a vehicle to emergency services when an accident occurs, providing accurate incident location and other vital information that dispatchers can use to send help much faster and more effectively to help save lives. With 25,670 fatalities in 2016 and over 135,000 serious injuries on EU roads and motorways in 2014, according to the European Transport Safety Council’s Road Safety Performance Index, eCall is estimated to reduce emergency response time by 40% in built-up areas and 50% in the countryside, saving as many as 2,500 lives and over EUR 130 billion in costs to society each year.
As a result, emergency services across Portugal have been running tests to demonstrate readiness to receive and respond to these new automated calls. As the global market leader in contact center solutions, Avaya was selected because of its ecosystem and open platform structure, enabling integration across a variety of different systems. The solutions deployed include: the creation of a new center in Porto to increase resiliency and geographic redundancy; a complete refresh of the existing emergency service data center in Lisbon; and an upgrade of the existing communication environment, including a subsequent integration into its dispatching application.
Markus Bornheim, Consulting Sales Engineer for Public Safety and Emergency Services at Avaya, and Vice Chair of the European Emergency Number Association (EENA) Technical Committee, said:
“Emergency Services communications require intricate coordination between a number of different channels, from voice calls, to calls from mobiles and now to eCall. It’s important to deliver a solution that can accommodate both present and future needs without putting undue pressure on those working in call centres or on the front line. Avaya’s eCall solution was designed to integrate with existing systems and provide a clear platform for further development. We are pleased to see our work achieve a strong result for Portugal, and look forward to extending this further elsewhere in Europe.”
Implementation of these solutions was carried out by Avaya’s local integration partner PAPTI/DECUNIFY, which worked with core tech provider Oecon and software developer Engelbart Software to adapt and modify the existing application development platform and allow integration with Portugal’s emergency services. As a result, Portugal’s 112 services can now receive, interpret and respond to messages sent through eCall; as well as integrate other eCall-associated technologies and similar third-party services for motorcycles, heavy goods vehicles, car manufacturers, assistance companies and automobile clubs. With Avaya’s support, solutions and architecture, Portugal achieved full preparation for the onset of eCall, in advance of the EU conformity assessment.
Colonel Vitor Judicibus, Head of the Critical Communications Multidisciplinary Team at the General Secretariat of Internal Administration (Secretaria-geral da Administração Interna) said:
“eCall is a major milestone for the European automotive and safety communities, with next-generation technology being widely deployed to help people and save lives. Providing Portugal’s dispatchers and emergency services call centre workers with the tools they need to incorporate eCall is essential to achieving the aims of this initiative. We are pleased that the Portuguese 112 service has been upgraded to fully respond to eCall, while also becoming faster, more reliable, and future-fit.”
Francisco Gomes, Deputy Secretary General for Technologies of the Ministry of Home Affairs (Secretaria-geral da Administração Interna) said:
“According to Nikola Tesla ‘Science is but a perversion of itself unless it has as its ultimate goal the betterment of humanity.’ I think the same about technology, and eCall is one of the best recent examples of a major improvement in Europe for emergency reaction. The overall purpose of being more efficient on preserving human life after traffic accidents will progress immensely with the introduction of eCall. Our Ministry tech teams and our partners together, made possible for Portugal to be fully ready to do the best in emergency situations.”
Avaya is a global leader in digital communications software, services and devices for businesses of all sizes. Our open, intelligent and customizable solutions for contact centers and unified communications offer the flexibility of Cloud, on-premises and hybrid deployments. Avaya shapes intelligent connections and creates seamless communication experiences for our customers, and their customers. Our professional planning, support and management services teams help optimize solutions, for highly reliable and efficient deployments. Avaya Holdings Corp. is traded on the NYSE under the ticker AVYA. For more information, please visit www.avaya.com.
Cautionary Note Regarding Forward-Looking Statements
This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," “our vision,” "plan," "potential," "preliminary," "predict," "should," "will," or “would” or the negative thereof or other variations thereof or comparable terminology and include, but are not limited to, expected cash savings and statements about expected growth and growth strategies, future investments and new technologies,. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Registration Statement on Form 10 filed with the Securities and Exchange Commission, may cause its actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. For a further list and description of such risks and uncertainties, please refer to the Company’s filings with the SEC that are available at www.sec.gov . The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this report may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.
Source: Avaya Newsroom
Iman Ghorayeb, +971-4-404-8275
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EEST | Tiedote
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EEST | Tiedote
ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B
Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EEST | Tiedote
Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan
Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EEST | Tiedote
Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste
WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EEST | Tiedote
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici
Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EEST | Tiedote
Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme